We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 17 for:    choroideremia

"Natural History" Study of Choroideremia

This study is currently recruiting participants.
Verified June 2017 by 4D Molecular Therapeutics
Sponsor:
ClinicalTrials.gov Identifier:
NCT02994368
First Posted: December 15, 2016
Last Update Posted: June 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
4D Molecular Therapeutics
  Purpose
The purpose of this study is to understand the rate of progression of all stages of choroideremia using a variety of assessments performed in the clinic including visual field measures, specialized photography of the eye and participant-reported visual problems

Condition Intervention
Choroideremia Other: Observation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multicenter Prospective Observational "Natural History" Study in Patients With Choroideremia

Resource links provided by NLM:


Further study details as provided by 4D Molecular Therapeutics:

Primary Outcome Measures:
  • Rate of progression of disease [ Time Frame: 2 years ]
    A variety of psychophysical, anatomical and image-based endpoints


Estimated Enrollment: 50
Study Start Date: December 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Observation
No intervention
Other: Observation

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with a clinical diagnosis of choroideremia
Criteria

Inclusion Criteria:

  • Healthy individuals with choroideremia (20/200 or better vision) willing to participate in an observational study and meeting the eligibility criteria.

Exclusion Criteria:

  1. Prior therapy with an AAV vector-based treatment
  2. Pre-existing eye conditions that would: (1) preclude future planned treatment in a therapeutic intent clinical trial (i.e. intravitreal injection), (2) interfere with the interpretation of study endpoints, and/ or put patient at risk for surgical complications
  3. Complicating systemic diseases that would preclude future enrollment in a therapeutic intent clinical trial
  4. Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02994368


Contacts
Contact: Jenny Holt (510) 505-2680 CHM@4dmoleculartherapeutics.com

Locations
United States, California
Retina and Vitreous Associates of Los Angeles Active, not recruiting
Los Angeles, California, United States
United States, Texas
Retina Foundation of the Southwest Active, not recruiting
Dallas, Texas, United States, 75251
United States, Utah
Moran Eye Center, University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Katie Rogers    801-581-2352    katie.rogers@utah.edu   
Principal Investigator: Paul Bernstein, MD         
Sponsors and Collaborators
4D Molecular Therapeutics
Investigators
Study Chair: Peter J Francis, MD PhD 4D Molecular Therapeutics
  More Information

Responsible Party: 4D Molecular Therapeutics
ClinicalTrials.gov Identifier: NCT02994368     History of Changes
Other Study ID Numbers: 4D-CHM-001-NH-0001
First Submitted: December 13, 2016
First Posted: December 15, 2016
Last Update Posted: June 19, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Keywords provided by 4D Molecular Therapeutics:
retinal degeneration
eye
REP-1 gene

Additional relevant MeSH terms:
Choroideremia
Eye Diseases, Hereditary
Eye Diseases
Choroid Diseases
Uveal Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked